menu toggle
Thursday, November 26 - Friday, November 27
Cencora will be closed on Thursday, November 26 in observance of the Thanksgiving holiday. There will be no deliveries on this day and our Customer Service and Customer Systems Support teams will be unavailable. Our offices will also be closed on Friday, November 27. While deliveries for non-refrigerated product will be attempted on Friday, our offices will be closed. Customer Service may be limited and Customer System Support will also be limited and available by email only. Please review our full holiday schedule for more detailed information and to plan your orders accordingly.

October 12, 2021

Ocular Therapeutix™ announces FDA approval of Supplemental New Drug Application (SNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itching associated with allergic conjunctivitis

Approval represents the first primarily office-based indication for DEXTENZA.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye,  announced on October 11 that the U.S. Food and Drug Administration (FDA) has approved its Supplemental New Drug Application (sNDA) to broaden the DEXTENZA label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, DEXTENZA is the first, FDA-approved, physician-administered intracanalicular insert capable of delivering a preservative-free drug for the treatment of ocular itching associated with allergic conjunctivitis with a single administration for up to 30 days. DEXTENZA originally received FDA approval in November 2018 for the treatment of ocular pain following ophthalmic surgery, followed by an expansion of the label to also include the treatment of ocular inflammation following ophthalmic surgery in June 2019.